New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's Disease

Neurotherapeutics

Volumn 5, Issue 3, 2008, Pages 409-414

  Zlokovic, Berislav V ^a  

^a Departments of Neurosurgery and Neurology   (United States)

Author keywords

amyloid peptide; angiogenesis; Blood brain barrier; dementia; ischemia; LRP; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; SERUM RESPONSE FACTOR;

ALZHEIMER DISEASE; ANGIOGENESIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN ISCHEMIA; CELL DIFFERENTIATION; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; GENE; HOMEOBOX; HUMAN; MDR1A GENE; MDR1B GENE; MEOX2 GENE; MYOCARDIN GENE; MYOCD GENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RECEPTOR INTRINSIC ACTIVITY; SRF GENE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BLOOD-BRAIN BARRIER; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; HUMANS; LDL-RECEPTOR RELATED PROTEIN 1; MODELS, BIOLOGICAL; RECEPTORS, IMMUNOLOGIC;

EID: 46749099351     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.05.011     Document Type: Article

References (67)

1. Hofman A., Ott A., Breteler M.M., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349 (1997) 151-154
2. Ruitenberg A., den Heijer T., Bakker S.L., et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 57 (2005) 789-794
3. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5 (2004) 347-360
4. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28 (2005) 202-208
5. de la Torre J.C. How do heart disease and stroke become risk factors for Alzheimer's disease?. Neurol Res 28 (2006) 637-644
6. Luchsinger J.A., Reitz C., Patel B., Tang M.X., Manly J.J., and Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol 64 (2007) 570-575
7. Rovelet-Lecrux A., Hannequin D., Raux G., et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38 (2006) 24-26
8. Hardy J. A hundred years of Alzheimer's disease research. Neuron 52 (2006) 3-13
9. Deane R., and Zlokovic B.V. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4 (2007) 191-197
10. Lee V.M., Balin B.J., Otvos Jr. L., and Trojanowski J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251 (1991) 675-678
11. Santacruz K., Lewis J., Spires T., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005) 476-481
12. Tanzi R.E. The synaptic Aβ hypothesis of Alzheimer disease. Nat Neurosci 8 (2005) 977-979
13. Ghiso J., and Frangione B. Amyloidosis and Alzheimer's disease. Adv Drug Deliv Rev 54 (2002) 1539-1551
14. Greenberg S.M., Gurol M.E., Rosand J., and Smith E.E. Amyloid angiopathy-related vascular cognitive impairment. Stroke 35 (2004) 2616-2619
15. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57 (2008) 178-201
16. Casserly I., and Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363 (2004) 1139-1146
17. Beach T.G., Wilson J.R., Sue L.I., et al. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol 113 (2007) 13-21
18. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., and Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277 (1997) 813-817
19. Vermeer S.E., Prins N.D., den Heijer T., Hofman A., Koudstaal P.J., and Breteler M.M. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348 (2003) 1215-1222
20. Chui H.C., Zarow C., Mack W.J., et al. Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol 60 (2006) 677-687
21. Griffin J.H., Zlokovic B., and Fernandez J.A. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol 39 (2002) 197-205
22. Gordon-Krajcer W., Kozniewska E., Lazarewicz J.W., and Ksiezak-Reding H. Differential changes in phosphorylation of tau at PHF-1 and 12E8 epitopes during brain ischemia and reperfusion in gerbils. Neurochem Res 32 (2007) 729-737
23. Wen Y., Yang S.H., Liu R., et al. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim Biophys Acta 1772 (2007) 473-483
24. Thomas T., Thomas G., McLendon C., Sutton T., and Mullan M. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380 (1996) 168-171
25. Iadecola C., Zhang F., Niwa K., et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2 (1999) 157-161
26. Niwa K., Younkin L., Ebeling C., et al. Aβ 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A 97 (2000) 9735-9740
27. 2+ signaling and the microvasculature in experimental mice models of Alzheimer's disease. Ann N Y Acad Sci 1097 (2007) 40-50
28. Smith C.D., Andersen A.H., Kryscio R.J., et al. Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 53 (1999) 1391-1396
29. Bookheimer S.Y., Strojwas M.H., Cohen M.S., et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 343 (2000) 450-456
30. Drake C.T., and Iadecola C. The role of neuronal signaling in controlling cerebral blood flow. Brain Lang 102 (2007) 141-152
31. Tanzi R.E., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120 (2005) 545-555
32. Zlokovic B.V., Yamada S., Holtzman D., Ghiso J., and Frangione B. Clearance of amyloid β-peptide from brain: transport or metabolism?. Nat Med 6 (2000) 718-719
33. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 32 (2001) 177-180
34. Tanzi R.E., Moir R.D., and Wagner S.L. Clearance of Alzheimer's Aβ peptide: the many roads to perdition. Neuron 43 (2004) 605-608
35. Holtzman D.M., and Zlokovic B.V. Role of Aβ transport and clearance in the pathogenesis and treatment of Alzheimer's disease. In: Sisodia S., and Tanzi R.E. (Eds). Alzheimer's disease: advances in genetics, molecular, and cellular biology (2007), Springer, New York 179-198
36. Snyder E.M., Nong Y., Almeida C.G., et al. Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci 8 (2005) 1051-1058
37. Haass C., and Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8 (2007) 101-112
38. Davis J., Xu F., Deane R., et al. Early-onset and robust cerebral microvascular accumulation of amyloid β-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid β-protein precursor. J Biol Chem 279 (2004) 20296-20306
39. Deane R., Wu Z., Sagare A., et al. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43 (2004) 333-344
40. Kumar-Singh S., Pirici D., McGowan E., et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 167 (2005) 527-543
41. Yan S.D., Chen X., Fu J., et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382 (1996) 685-691
42. Giri R., Shen Y., Stins M., et al. β-Amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol 279 (2000) C1772-C1781
43. Deane R., Du Yan S., Submamaryan R.K., et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9 (2003) 907-913
44. LaRue B., Hogg E., Sagare A., et al. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-β peptide in wild type and Alzheimer's Tg2576 mice. J Neurosci Methods 138 (2004) 233-242
45. Donahue J.E., Flaherty S.L., Johanson C.E., et al. RAGE, LRP-1, and amyloid-β protein in Alzheimer's disease. Acta Neuropathol 112 (2006) 405-415
46. Herring A., Yasin H., Ambrée O., Sachser N., Paulus W., and Keyvani K. Environmental enrichment counteracts Alzheimer's neurovascular dysfunction in TgCRND8 mice. Brain Pathol 18 (2008) 32-39
47. Martel C.L., Mackic J.B., McComb J.G., Ghiso J., and Zlokovic B.V. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid β in guinea pigs. Neurosci Lett 206 (1996) 157-160
48. Mackic J.B., Bading J., Ghiso J., et al. Circulating amyloid-β peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol 38 (2002) 303-313
49. Zlokovic B.V., Hyman S., McComb J.G., Lipovac M.N., Tang G., and Davson H. Kinetics of arginine-vasopressin uptake at the blood-brain barrier. Biochim Biophys Acta 1025 (1990) 191-198
50. Zlokovic B.V., Mackic J.B., Djuricic B., and Davson H. Kinetic analysis of leucine-enkephalin cellular uptake at the luminal side of the blood-brain barrier of an in situ perfused guinea-pig brain. J Neurochem 53 (1989) 1333-1340
51. Zlokovic B.V., Begley D.J., and Chain-Eliash D.G. Blood-brain barrier permeability to leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal amino acid (tyrosine). Brain Res 336 (1985) 125-132
52. Segal M.B., Preston J.E., Collis C.S., and Zlokovic B.V. Kinetics and Na independence of amino acid uptake by blood side of perfused sheep choroid plexus. Am J Physiol 258 (1990) F1288-F1294
53. Shibata M., Yamada S., Kumar S.R., et al. Clearance of Alzheimer's amyloid-β (1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106 (2000) 1489-1499
54. Cirrito J.R., Deane R., Fagan A.M., et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Invest 115 (2005) 3285-3290
55. Bell R.D., Sagare A.P., Friedman A.E., et al. Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27 (2007) 909-918
56. Monro O.R., Mackic J.B., Yamada S., et al. Substitution at codon 22 reduces clearance of Alzheimer's amyloid-β peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging 23 (2002) 405-412
57. Van Uden E., Mallory M., Veinbergs I., Alford M., Rockenstein E., and Masliah E. Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J Neurosci 22 (2002) 9298-9304
58. Tamaki C., Ohtsuki S., Iwatsubo T., et al. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid β-peptide by the liver. Pharm Res 23 (2006) 1407-1416
59. von Arnim C.A., Kinoshita A., Peltan I.D., et al. The low density lipoprotein receptor-related protein (LRP) is a novel β-secretase (BACE1) substrate. J Biol Chem 280 (2005) 17777-17785
60. Sagare A., Deane R., Bell R.D., et al. Clearance of amyloid-β by circulating lipoprotein receptors. Nat Med 13 (2007) 1029-1031
61. Farkas E., and Luiten P.G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 64 (2001) 575-611
62. Bailey T.L., Rivara C.B., Rocher A.B., and Hof P.R. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res 26 (2004) 573-578
63. Wu Z., Guo H., Chow N., et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 11 (2005) 959-965
64. Paris D., Townsend K., Quadros A., et al. Inhibition of angiogenesis by Aβ peptides. Angiogenesis 7 (2004) 75-85
65. Paris D., Patel N., DelleDonne A., Quadros A., Smeed R., and Mullan M. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett 366 (2004) 80-85
66. Deane R., Wu Z., and Zlokovic B.V. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier. Stroke 35 (2004) 2628-2631
67. Chow N., Bell R.D., Deane R., et al. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc Natl Acad Sci U S A 104 (2007) 823-828